Survival is not the only valuable end point in melanoma screening

Journal of Investigative Dermatology

Volumn 132, Issue 5, 2012, Pages 1332-1337

  Curiel Lewandrowski, Clara ^a   Kim, Caroline C ^b   Swetter, Susan M ^c   Chen, Suephy C ^d   Halpern, Allan C ^e   Kirkwood, John M ^f   Leachman, Sancy A ^g   Marghoob, Ashfaq A ^e   Ming, Michael E ^h   Grichnik, James M ⁱ  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c STANFORD UNIVERSITY   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER SCREENING; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; EARLY DIAGNOSIS; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; MEDICAL CARE; MELANOMA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW;

EID: 84862777765     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2012.3     Document Type: Article

References (59)

1. ACS Cancer Facts & Figures (2011). http://www. cancer.org/acs/groups/ content/@epidemiology surveilance/documents/document/acspc-029771. pdf
2. Agnese DM, Abdessalam SF, Burak WE Jr et al. (2003) Cost-effectiveness of sentinel lymph node biopsy in thin melanomas. Surgery 134:542-7
3. Aitken JF, Elwood JM, Lowe JB et al. (2002) A randomised trial of population screening for melanoma. J Med Screen 9:33-7 (Pubitemid 34327140)
4. Aitken JF, Janda M, Elwood M et al. (2006) Clinical outcomes from skin screening clinics within a community-based melanoma screening program. J Am Acad Dermatol 54:105-14 (Pubitemid 41832466)
5. Albert LS, Rhodes AR, Sober AJ (1990) Dysplastic melanocytic nevi and cutaneous melanoma: markers of increased melanoma risk for affected persons and blood relatives. J Am Acad Dermatol 22:69-75 (Pubitemid 20035723)
6. Alexandrescu DT (2009) Melanoma costs: a dynamic model comparing estimated overall costs of various clinical stages. Dermatol Online J 15:1
7. Banky JP, Kelly JW, English DR et al. (2005) Incidence of new and changed nevi and melanomas detected using baseline images and dermoscopy in patients at high risk for melanoma. Arch Dermatol 141:998-1006 (Pubitemid 46165523)
8. Beddingfield III FC (2003) Melanoma: a decision analysis to estimate the effectiveness and costeffectiveness of screening and an analysis of the relevant epidemiology of the disease. http://www.rand.org/publications/RGSD/RGSD167/
9. Brady MS, Oliveria SA, Christos PJ et al. (2000) Patterns of detection in patients with cutaneous melanoma. Cancer 89:342-7
10. Braun-Falco M, Schempp W, Weyers W (2009) Molecular diagnosis in dermatopathology: what makes sense, and what doesn't. Exp Dermatol 18:12-23
11. Buettner PG, Leiter U, Eigentler TK et al. (2005) Development of prognostic factors and survival in cutaneous melanoma over 25 years: An analysis of the Central Malignant Melanoma Registry of the German Dermatological Society. Cancer 103:616-24
12. Carli P, De Giorgi V, Crocetti E et al. (2004) Improvement of malignant/benign ratio in excised melanocytic lesions in the 'dermoscopy era': a retrospective study 1997-2001. Br J Dermatol 150:687-92 (Pubitemid 38586219)
13. Chamberlain AJ, Fritschi L, Giles GG et al. (2002) Nodular type and older age as the most significant associations of thick melanoma in Victoria, Australia. Arch Dermatol 138:609-14
14. Cho E, Rosner BA, Feskanich D et al. (2005) Risk factors and individual probabilities of melanoma for whites. J Clin Oncol 23:2669-75 (Pubitemid 46179456)
15. Coit DG, Andtbacka R, Bichakjian CK et al. (2009) Melanoma. J Natl Compr Canc Netw 7:250-75
16. Farmer ER, Gonin R, Hanna MP (1996) Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists. Hum Pathol 27:528-31 (Pubitemid 26187274)
17. Federman DG, Kravetz JD, Kirsner RS (2002) Skin cancer screening by dermatologists: prevalence and barriers. J Am Acad Dermatol 46:710-4
18. Feit NE, Dusza SW, Marghoob AA (2004) Melanomas detected with the aid of total cutaneous photography. Br J Dermatol 150:706-14 (Pubitemid 38586222)
19. Feng Z, Wu X, Chen V, Velie E et al. (2011) Incidence and survival of desmoplastic melanoma in the United States, 1992-2007. J Cutan Pathol 38:616-24
20. Fortes C, Mastroeni S, Bakos L et al. (2010) Identifying individuals at high risk of melanoma: a simple tool. Eur J Cancer Prev 19:393-400
21. Freedberg KA, Geller AC, Miller DR et al. (1999) Screening for malignant melanoma: a costeffectiveness analysis. J Am Acad Dermatol 41:738-45 (Pubitemid 29514030)
22. From L, Marret L, Rosen C et al. (2007) Screening for Skin Cancer: A Systematic Review. A Quality Initiative of the Program in Evidencebased Care (PEBC). Cancer Care Ontario (CCO). 19 June 2007
23. Geller AC (2009) Educational and screening campaigns to reduce deaths from melanoma. [Review] [59 refs]. Hematol Oncol Clin North Am 23:515-27
24. Geller AC, Elwood M, Swetter SM et al. (2009a) Factors related to the presentation of thin and thick nodular melanoma from a populationbased cancer registry in Queensland Australia. Cancer 115:1318-27
25. Geller AC, Emmons K, Brooks DR et al. (2003) Skin cancer prevention and detection practices among siblings of patients with melanoma. J Am Acad Dermatol 49:631-8 (Pubitemid 37210275)
26. Geller AC, Greinert R, Sinclair C et al. (2010) A nationwide population-based skin cancer screening in Germany: proceedings of the first meeting of the International Task Force on Skin Cancer Screening and Prevention (September 24 and 25, 2009). Cancer Epidemiol 34:355-8
27. Geller AC, Johnson TM, Miller DR et al. (2009b) Factors associated with physician discovery of early melanoma in middle-aged and older men. Arch Dermatol 145:409-14
28. Geller AC, Miller DR, Swetter SM et al. (2006a) A call for the development and implementation of a targeted national melanoma screening program. Arch Dermatol 142:504-7 (Pubitemid 43671652)
29. Geller J, Swetter SM, Leyson J et al. (2006b) Crafting a melanoma educational campaign to reach middle-aged and older men. J Cutan Med Surg 10:259-68 (Pubitemid 351517508)
30. Girgis A, Clarke P, Burton RC et al. (1996) Screening for melanoma by primary health care physicians: a cost-effectiveness analysis. J Med Screen 3:47-53 (Pubitemid 126736075)
31. Goldman L (2005) Cost-effectiveness in a flat world: can ICDs help the United States get rhythm? N Engl J Med 353:1513-5 (Pubitemid 41400928)
32. High WA (2008) Malpractice in dermatopathology: principles, risk mitigation, and opportunities for improved care for the histologic diagnosis of melanoma and pigmented lesions. Clin Lab Med 28:261-84, vii (Pubitemid 351635820)
33. Janda M, Lowe JB, Elwood M et al. (2006) Do centralised skin screening clinics increase participation in melanoma screening (Australia)? Cancer Causes Control 17:161-8 (Pubitemid 43121765)
34. Kamposioras K, Pentheroudakis G, Pectasides D et al. (2010) Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature. Crit Rev Oncol Hematol. 78:112-26
35. Kasparian NA, McLoone JK, Butow PN (2009) Psychological responses and coping strategies among patients with malignant melanoma: a systematic review of the literature. Arch Dermatol 145:1415-27
36. Kasparian NA, McLoone JK, Meiser B et al. (2010) Skin cancer screening behaviours among individuals with a strong family history of malignant melanoma. Br J Cancer 103:1502-9
37. Katalinic A, Kunze U, Schäfer T (2003) Epidemiology of cutaneous melanoma and nonmelanoma skin cancer in Schleswig-Holstein, Germany: incidence, clinical subtypes, tumour stages and localization (epidemiology of skin cancer). Br J Dermatol 149:1200-6 (Pubitemid 38058096)
38. Linos E, Swetter SM, Cockburn MG et al. (2009) Increasing burden of melanoma in the United States. J Invest Dermatol 129:1666-74
39. Losina E, Walensky RP, Geller A et al. (2007) Visual screening for malignant melanoma: a cost-effectiveness analysis. Arch Dermatol 143:21-8 (Pubitemid 46143192)
40. Mandelblatt J, Saha S, Teutsch S et al. (2003) The cost-effectiveness of screening mammography beyond age 65 years: a systematic review for the US Preventive Services Task Force. Ann Intern Med 139:835-42
41. Mar V, Wolfe R, Kelly JW (2011) Predicting melanoma risk for the Australian population. Australas J Dermatol 52:109-16
42. McLaughlin CC, Wu XC, Jemal A et al. (2005) Incidence of noncutaneous melanomas in the US. Cancer 103:1000-7
43. Menzies SW, Kreusch J, Byth K et al. (2008) Dermoscopic evaluation of amelanotic and hypomelanotic melanoma. Arch Dermatol 144:1120-7
44. Pennie ML, Soon SL, Risser JB et al. (2007) Melanoma outcomes for Medicare patients: association of stage and survival with detection by a dermatologist vs a nondermatologist. Arch Dermatol 143:488-94 (Pubitemid 46631647)
45. Rademaker M, Oakley A (2010) Digital monitoring by whole body photography and sequential digital dermoscopy detects thinner melanomas. J Prim Health Care 2:268-72
46. Robinson JK, Turrisi R, Stapleton J (2007) Examination of mediating variables in a partner assistance intervention designed to increase performance of skin self-examination. J Am Acad Dermatol 56:391-7 (Pubitemid 46273848)
47. Schneider JS, Moore II DH, Mendelsohn ML (2008) Screening program reduced melanoma mortality at the Lawrence Livermore National Laboratory, 1984 to 1996. J Am Acad Dermatol 58:741-9
48. Shaikh WR, Xiong M, Weinstock MA (2011) The Contribution of Nodular Subtype to Melanoma Mortality in the United States, 1978 to 2007. Arch Dermatol. e-pub ahead of print 9 September 2011
49. Shoo BA, Sagebiel RW, Kashani-Sabet M (2010) Discordance in the histopathologic diagnosis of melanoma at a melanoma referral center. J Am Acad Dermatol 62:751-6
50. Shuster S (2009) Malignant melanoma: how error amplification by screening creates spurious disease. Br J Dermatol 161:977-9
51. Swetter SM, Geller AC, Kirkwood JM (2004) Melanoma in the older person. Oncology (Williston Park) 18:1187-96
52. Torres-Cabala CA, Plaza JA, Diwan AH et al. (2010) Severe architectural disorder is a potential pitfall in the diagnosis of small melanocytic lesions. Cutan Pathol 37:860-5
53. Ubel PA, Hirth RA, Chernew ME et al. (2003) What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 163:1637-41 (Pubitemid 36898950)
54. Wang SQ, Kopf AW, Koenig K et al. (2004) Detection of melanomas in patients followed up with total cutaneous examinations, total cutaneous photography, and dermoscopy. J Am Acad Dermatol 50:15-20 (Pubitemid 38095645)
55. Weinstein MC, Goldie SJ, Losina E et al. (2001) Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med 134: 440-50 (Pubitemid 32225945)
56. Welch HG, Black WC (2010) Overdiagnosis in cancer. J Natl Cancer Inst 102:605-13
57. Welch HG, Woloshin S, Schwartz LM (2005) Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ 331:481
58. Wolff T, Tai E, Miller T (2009) Screening for skin cancer: an update of the evidence for the US preventive services task force. Ann Intern Med 150:194-8
59. Youl PH, Baade PD, Janda M et al. (2007) Diagnosing skin cancer in primary care: how do mainstream general practitioners compare with primary care skin cancer clinic doctors? Med J Aust 187:215-20